Comparative Analysis of Adverse Drug Reactions Caused by Iodixanol and Iohexol

Abstract

Abstract: Objective To investigate the characteristics of adverse drug reactions (ADRs) caused by iodixanol and iohexol in order to provide reference for safe drug use in clinical practice. Methods Reports of ADR caused by iodixanol and iohexol were selected from database of Hangzhou Drug and Medical Devices Adverse Reaction Monitoring Center from January 2013 to April 2017 and divided into two groups. Patients' information, major manifestations, proportion of serious ADR, proportion of delayed ADR and latent time of ADR were compared. Statistical methods such as statistical tables, statistical graphs, chi-square test, t-test, survival analysis and Breslow test were used to deal with the data. Results A total of 228 reports were entered, including 73 cases caused by iodixanol and 155 cases caused by iohexol. Mean age of iodixanol group was older than iohexol group (P<0.05). There was no statistically significant difference (P=0.69) in proportion of serious ADR between the two groups: 6.85% for iodixanol vs. 8.39% for iohexol. Proportion of delayed ADR of iodixanol group (69.86%) was higher than iohexol group (7.10%) (P<0.01). Average latent time of iodixanol group was longer than iohexol group (P<0.01). Conclusion Iodixanol and iohexol have some different clinical manifestations in ADR, iodixanol had higher proportion of delayed ADR and longer latent time, so maybe it's necessary to prolong medical observation time properly after administration of iodixanol.

Key words: iodixanol, iohexol, adverse drug reaction

CLC Number:

R994.11

XU Zhi-xiang. Comparative Analysis of Adverse Drug Reactions Caused by Iodixanol and Iohexol[J]. Chinese Journal of Pharmacovigilance, 2018, 15(2): 125-128.

References

[1] Mccullough P A, Capasso P. Patient discomfort associated with the use of intra-arterial iodinated contrast media: a meta-analysis of comparative randomized controlled trials[J/OL].(2011-05-24)[2017-08-03].https://bmcmedimaging.biomedcentral.com/articles/10.1186/1471-2342-11-12.
[2] Zhang B C, Hou L, Lv B, et al. Post-marketing surveillance study with iodixanol in 20185 Chinese patients from routine clinical practices[J/OL].(2014-01-22)[2017-08-03].http://www.birpublications.org/doi/full/10.1259/bjr.20130325.
[3] H ussler M D. Safety and patient comfort with iodixanol: a postmarketing surveillance study in 9515 patients undergoing diagnostic CT examinations[J]. Acta Radiologica, 2010,51(8):924-933.
[4] Webb J A, Stacul F, Thomsen H S, et al. Late adverse reactions to intravascular iodinated contrast media[J]. European Radiology, 2003,13(1):181-184.
[5] Fransson S G, Stenport G, Andersson M. Immediate and late adverse reactions in coronary angiography. A comparison between iodixanol and ioxaglate[J]. Acta Radiologica, 1996,37(2):218-222.
[6] Rydberg J, Charles J, Aspelin P. Frequency of late allergy-like adverse reactions following injection of intravascular non-ionic contrast media. A retrospective study comparing a non-ionic monomeric contrast medium with a non-ionic dimeric contrast medium[J]. Acta Radiologica, 1998,39(3):219-222.
[7] 陈韵岱，陈纪言，傅国胜，等. 碘对比剂血管造影应用相关不良反应中国专家共识[J]. 中国介入心脏病学杂志， 2014，22(6):341-348.
[8] 杨跃进，李一石. 重视非离子型冠脉造影剂引发的过敏样反应[J]. 中国药物警戒，2010，7(5):284-285.
[9] Heinzerling L M, Tomsitz D, Anliker M D. Is drug allergy less prevalent than previously assumed? A 5-year analysis[J]. British Journal of Dermatology, 2012,166(1):107-114.
[10] Doa I, Blanca-López N, Torres M J, et al. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients[J]. Journal of Investigational Allergology & Clinical Immunology, 2012,22(5):363-371.
[11] 庄伟，刘玉清，李一石，等. 我院5年间冠脉介入术中碘造影剂过敏反应监测报告分析[J]. 中国药物警戒，2013，10(12):734-736.
[12] Egbert R E, De Cecco C N, Schoepf U J, et al. Delayed adverse reactions to the parenteral administration of iodinated contrast media[J]. American Journal of Roentgenology, 2014,203(6):1163-1170.
[13] Gómez E, Ariza A, Blanca-López N, et al. Nonimmediate hypersensitivity reactions to iodinated contrast media[J]. Current Opinion in Allergy & Clinical Immunology, 2013,13(4):345-353.
[14] Burkhart C, Britschgi M, Strasser I, et al. Non-covalent presentation of sulfamethoxazole to human CD4+ T cells is independent of distinct human leucocyte antigen-bound peptides[J]. Clinical & Experimental Allergy, 2002,32(11):1635-1643.
[15] Kanny G, Pichler W, Morisset M, et al. T cell-mediated reactions to iodinated contrast media: Evaluation by skin and lymphocyte activation tests[J]. Journal of Allergy & Clinical Immunology, 2005,115(1):179-185.
[16] Torres M J, Mayorga C, Cornejogarcia J A, et al. Monitoring non-immediate allergic reactions to iodine contrast media[J]. Clinical & Experimental Immunology, 2008,152(2):233-238.
[17] Antunez C, Barbaud A, Gomez E, et al. Recognition of iodixanol by dendritic cells increases the cellular response in delayed allergic reactions to contrast media[J]. Clinical & Experimental Allergy, 2011,41(5):657-664.
[18] Munechika H, Hiramatsu Y, Kudo S, et al. A prospective survey of delayed adverse reactions to iohexol in urography and computed tomography[J]. European Radiology, 2003,13(1):185-194.
[19] Hosoya T, Yamaguchi K, Akutsu T. Delayed adverse reactions to iodinated contrast media and their risk factors[J]. Radiation Medicine, 2000,18(1):39-45.
[20] 中华医学会放射学分会对比剂安全使用工作组. 碘对比剂使用指南(第2版)[J]. 中华医学杂志， 2014， 94(43):3363-3369.